Genfit S.A. (FRA:XUP)

Market Cap	715.35M +279.4%
Revenue (ttm)	70.85M +0.2%
Net Income	-85.97M
EPS	-1.72
Shares Out	n/a
PE Ratio	n/a
Forward PE	52.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	14.20
Previous Close	13.80
Day's Range	14.20 - 14.20
52-Week Range	3.01 - 14.86
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 29, 2026

About Genfit

Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcin...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 161
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XUP

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error